Printer Friendly

Articles from M2 Pharma (August 7, 2017)

1-14 out of 14 article(s)
Title Author Type Words
Avelas Biosciences Starts Phase 2 Study of AVB-620 to Further Evaluate Fluorescent Signals in Malignant and Nonmalignant Tissue. 236
Biohaven names Julia P. Gregory to board. 190
Biohaven treats spinocerebellar ataxia patients with trigriluzole under Phase 2/3 trial; Expects topline data in Q4 2017. 285
Fresenius Medical Care to acquire NxStage Medical. 176
Janssen Biotech's Sirukumab fails to gain US FDA Comittee approval for rheumatoid arthritis. 191
LEO Pharma enters multi-target multi-year collaboration with HitGen. 228
Lilly's Lasmiditan Meets Primary and Secondary Endpoints in SPARTAN Study for the Acute Treatment of Migraine. 381
NHS England initiates HIV PrEP study. 239
Omeros' OMS721 Receives Orphan Drug Designation for Treatment of IgA Nephropathy. 337
Perrigo awarded tentative approval from US FDA for generic version of Mirvaso Gel to treat rosacea. 153
Radiotherapy Market to Reach USD 7.2bn by 2023, Research and Markets Forecasts. 285
Rx30 to Use Creative Pharmacist eCare Platform to Help Pharmacies Deliver More Efficient Clinical Services. 279
Takeda Pharmaceutical signs cardiovascular development collaboration with Cardurion Pharmaceuticals. 147
US CDC Awards USD 200m in 2017 to Meet Growing Infectious Disease Threats. 452

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters